Leerink Partnrs Brokers Decrease Earnings Estimates for GPCR

Structure Therapeutics Inc. (NASDAQ:GPCR) – Investment analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for shares of Structure Therapeutics in a research report issued on Thursday, May 8th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of $1.78 per share for the year, down from their prior forecast of $1.80. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share. Leerink Partnrs also issued estimates for Structure Therapeutics’ FY2029 earnings at $0.97 EPS.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03).

GPCR has been the subject of several other reports. William Blair started coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They set an “outperform” rating for the company. Citigroup began coverage on Structure Therapeutics in a research note on Friday, May 2nd. They set a “buy” rating and a $60.00 price objective for the company. Finally, HC Wainwright cut their target price on Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Monday. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics presently has an average rating of “Buy” and an average price target of $78.00.

Structure Therapeutics Stock Performance

Structure Therapeutics stock opened at $23.89 on Monday. Structure Therapeutics has a fifty-two week low of $13.22 and a fifty-two week high of $62.74. The stock’s 50 day simple moving average is $20.98 and its two-hundred day simple moving average is $26.75. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -32.28 and a beta of -1.69.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Aberdeen Group plc increased its position in Structure Therapeutics by 45.2% during the 1st quarter. Aberdeen Group plc now owns 248,899 shares of the company’s stock valued at $4,308,000 after purchasing an additional 77,511 shares during the period. Invesco Ltd. lifted its position in shares of Structure Therapeutics by 6.1% during the first quarter. Invesco Ltd. now owns 394,386 shares of the company’s stock valued at $6,827,000 after buying an additional 22,619 shares during the last quarter. National Bank of Canada FI boosted its holdings in shares of Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock valued at $51,000 after buying an additional 2,766 shares in the last quarter. ANTIPODES PARTNERS Ltd lifted its position in Structure Therapeutics by 310.7% during the first quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company’s stock valued at $74,000 after acquiring an additional 3,213 shares during the last quarter. Finally, Readystate Asset Management LP grew its holdings in Structure Therapeutics by 129.9% in the first quarter. Readystate Asset Management LP now owns 481,241 shares of the company’s stock worth $8,330,000 after purchasing an additional 271,899 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.